Behandling med dopaminagonister og udvikling af hjerteklapsygdom hos patienter med hyperprolaktinæmi

Translated title of the contribution: Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patients.

Charlotte Steffensen, Merete Lund Mægbæk, Peter Laurberg, Marianne Andersen, Caroline Michaela Nervil Kistorp, Helene Nørrelund, Jakob Dal, Jens Otto Lunde Jørgensen

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Treatment with dopamin agonists, particularly cabergoline, is the primary and preferred therapy for prolactinomas and symptomatic hyperprolactinaemia due to its effectiveness and tolerability. However, an association has been demonstrated between fibrotic heart valve disease and high-dose dopamin agonist use in patients with Parkinson's disease in several echocardiographic studies. Such observations have prompted a number of studies of valvular function in cabergoline-treated hyperprolactinaemia patients. These studies have failed to show an increased prevalence of clinically significant valvular regurgitation.

Translated title of the contributionDopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patients.
Original languageDanish
JournalUgeskrift for Laeger
Volume176
Issue number1
Pages (from-to)58-60
Number of pages3
ISSN0041-5782
Publication statusPublished - 6 Jan 2014

Fingerprint

Dive into the research topics of 'Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patients.'. Together they form a unique fingerprint.

Cite this